Squarepoint
AVDL

Squarepoint’s Avadel Pharmaceuticals AVDL Stock Holding History

Squarepoint’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-420,072
Closed -$9.05M – 4258
2025
Q4 		$9.05M Buy
420,072
+134,612
+47% +$2.61M 0.01% 1124
2025
Q3 		$4.36M Buy
285,460
+151,239
+113% +$1.97M ﹤0.01% 1553
2025
Q2 		$1.19M Sell
134,221
-131,864
-50% -$1.16M ﹤0.01% 2513
2025
Q1 		$2.08M Buy
266,085
+138,496
+109% +$1.16M ﹤0.01% 2060
2024
Q4 		$1.34M Sell
127,589
-1,026
-0.8% -$12.5K ﹤0.01% 2787
2024
Q3 		$1.69M Buy
+128,615
New +$1.96M ﹤0.01% 2191
2023
Q4 		– Sell
-14,582
Closed -$150K – 3996
2023
Q3 		$150K Buy
+14,582
New +$195K ﹤0.01% 3487
2021
Q3 		– Sell
-28,162
Closed -$190K – 2894
2021
Q2 		$190K Buy
28,162
+16,194
+135% +$129K ﹤0.01% 2853
2021
Q1 		$108K Sell
11,968
-44,698
-79% -$361K ﹤0.01% 2884
2020
Q4 		$379K Sell
56,666
-4,499
-7% -$28.1K ﹤0.01% 2032
2020
Q3 		$308K Buy
+61,165
New +$445K ﹤0.01% 1772

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Squarepoint's AVDL Position: Q1 2026 in Review

Squarepoint sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 420,072 shares — an estimated $9.05M sold.

Squarepoint first reported a position in AVDL in Q3 2020 and held it in 11 quarters. The position peaked at $9.05M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Squarepoint reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 420,072 Avadel Pharmaceuticals shares in Q1 2026, an estimated $9.05M.
  • Squarepoint first reported a position in Avadel Pharmaceuticals in Q3 2020 and held it in 11 quarters.
  • Squarepoint's Avadel Pharmaceuticals position peaked at $9.05M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.